- March 29, 2019 - What’s New and What’s Next in the Treatment of MDS?
- Mikkael A. Sekeres, MD, MS, and David P. Steensma, MD, FACP
The MDS Foundation is pleased to have collaborated with MediCom Worldwide, Inc. on the development of this activity.Myelodysplastic syndromes are a group of small-incidence malignancies that represent a significant challenge to many community oncologists. In this activity, participants will hear from two key experts about a variety of topics including, but not limited to: personalized risk stratification, iron overload, immunotherapies, and new strategies for treating lower- and higher-risk MDS. Join Dr. Sekeres and Dr. Steensma as they discuss incorporating molecular abnormalities into diagnosis and prognosis, and where luspatercept and imetelstat may fit into the future of MDS treatment. Learn More and Begin Course
- December 28, 2018 - ASH 2018 Annual Meeting Highlights in MDS
- Ehab Atallah, MD; Guillermo Garcia-Manero, MD; Shyamala C. Navada, MD, MSCR; David P. Steensma, MD, FACP; Eytan M. Stein, MD
In this activity, participants will hear key highlights taken from of a select group of abstracts which focused on some of the most impactful data in myelodysplastic syndromes (MDS), presented at the 2018 American Society of Hematology (ASH) 60th Annual Meeting. Learn More and Begin Course
- December 17, 2018 - Diagnostic Challenges in MDS
- Eric Padron, MD
Clinicians face a number of challenges when diagnosing a patient with myelodysplastic syndromes (MDS). In this activity, Dr. Eric Padron discusses the molecular basis of MDS and its requirements for diagnosis. He also explains diagnostic mimics and precursor conditions, and which diagnostic criteria to utilize in your practice. Learn More and Begin Course
- December 12, 2018 - Anemia in Low-Risk MDS: Current Treatment and Trials in Progress
- Steven D. Gore, MD
A majority of patients with low-risk MDS will develop symptomatic anemia over time. Practitioners are often challenged with the goal to minimize symptoms, improve blood counts, and decrease transfusions. In this activity, Dr. Gore reviews the efficacy and safety data of current and emerging therapies for anemia in low-risk MDS. Learn More and Begin Course
- November 30, 2018 - The Future of Targeted Therapy in MDS
- Shannon R. McCurdy, MD
In order to tailor a treatment approach to each individual patient, it is vital to understand how to identify molecular markers to select targeted therapies. Practitioners may be challenged with making these therapeutic decisions without sufficient knowledge of efficacy and safety data on available targeted therapies. The development of potential future targeted agents increases the burden on healthcare providers. In this activity, Dr. McCurdy reviews current and emerging targeted therapies and their role in the treatment of MDS. Learn More and Begin Course
- October 31, 2018 - Strategies for Optimizing Care in MDS Based on Level of Risk
- Olatoyosi Odenike, MD, and Eunice S. Wang, MD
Oncology nurses are at the forefront of providing supportive care to patients when new therapies and treatment plans are initiated. They must balance potential benefits with tolerability and risks for side effects. In this activity, Dr. Olatoyosi Odenike discusses treatment strategies for low-risk MDS and evaluates how recent advances and emerging options are impacting the current standard of care. Dr. Eunice S. Wang summarizes strategies for the appropriate use of several different types of drug therapies and discusses clinical trial data that will help guide the management of high-risk MDS patients. Learn More and Begin Course
- August 29, 2018 - Optimizing Outcomes in High-risk MDS: Current and Emerging Standards of Care - Eunice S. Wang, MD
- In this activity, Dr. Wang summarizes strategies for optimizing patient selection and treatment using current standards of care and available data from clinical trials. She also identifies strategies for the appropriate use of hypomethylating agents and discusses clinical trial data that will help guide future directions in managing high-risk MDS patients. Learn More and Begin Course
- August 13, 2018 - A Look at Pevonedistat and Other Ongoing Clinical Trials in MDS - Michael R. Savona, MD
In this installment of the Clinical Trials Spotlight, Managing MDS interviews Dr. Michael R. Savona, Director of Hematology Research and Associate Professor of Medicine at Vanderbilt University Medical Center, about ongoing clinical trials being conducted in patients with MDS. Learn More
This activity was created by Managing MDS, an educational initiative by MediCom Worldwide, Inc., an accredited provider of continuing medical education and non-CE activities. Selecting this activity will bring you to ManagingMDS.com.
- July 30, 2018 - Prognostic Risk Assessment in MDS: Incorporating the IPSS-R into Practice - Rami S. Komrokji, MD
- Dr. Rami Komrokji discusses the role of current prognostic risk assessments, including the IPSS-R, and how these tools can be used to individualize treatment for patients with MDS, including the important role of genetic testing as a complement to prognostic risk assessments.
Learn More and Begin Course
- April 23, 2018 - The INSPIRE Clinical Trial: Investigating Novel Treatments for High-risk MDS Patients - Jamile M. Shammo, MD, FASCP, FACP
In this first installment in the Clinical Trials Spotlight, Managing MDS interviews Dr. Jamile Shammo, Professor of Medicine at Rush University Medical Center, concerning the INSPIRE trial, a phase 3 trial of rigosertib versus physician’s choice of treatment in MDS patients following failure of a hypomethylating agent (HMA). Learn More
This activity was created by Managing MDS, an educational initiative by MediCom Worldwide, Inc., an accredited provider of continuing medical education and non-CE activities. Selecting this activity will bring you to ManagingMDS.com.
- January 12, 2018 - Practice-changing trials to watch for in 2018 - Guillermo Garcia-Manero, MD
Dr. Garcia-Manero provides a concise summary of clinical trials and forthcoming data in 2018 that have the potential to change the way we treat MDS. Learn More and Watch the Video
This activity was created by Managing MDS, an educational initiative by MediCom Worldwide, Inc., an accredited provider of continuing medical education and non-CE activities. Selecting this activity will bring you to ManagingMDS.com.
- October 31, 2017 - When can I stop my patient’s demethylating agent? - Stuart Goldberg, MD
Dr. Goldberg discusses when it is appropriate to stop a patient’s demethylating agent, taking into consideration age and IPSS-R risk group. Learn More and Watch the Video
This activity was created by Managing MDS, an educational initiative by MediCom Worldwide, Inc., an accredited provider of continuing medical education and non-CE activities. Selecting this activity will bring you to ManagingMDS.com.
- September 28, 2017 - How do I diagnose a patient with identified mutations who has a non-diagnostic bone marrow biopsy? - Rafael Bejar, MD, PhD
In this activity, Dr. Bejar will discuss a scenario where a patient with unexplained cytopenias is suspected of having MDS, but has a non-diagnostic bone marrow biopsy and a normal karyotype. Learn More and Watch the Video
This activity was created by Managing MDS, an educational initiative by MediCom Worldwide, Inc., an accredited provider of continuing medical education and non-CE activities. Selecting this activity will bring you to ManagingMDS.com.
- July 18, 2017 - Mobile Applications to Support Health Self-Management - Sandra E. Kurtin, RN, MS, AOCN©, ANP-C
In this Clinical Commentary, Sandra Kurtin discusses the benefits of teaching patients and caregivers to use a healthcare mobile app to self-manage their MDS. Learn More and Watch the Video
This activity was created by Managing MDS, an educational initiative by MediCom Worldwide, Inc., an accredited provider of continuing medical education and non-CE activities. Selecting this activity will bring you to ManagingMDS.com.
